Forced COX-2 expression induces PGE2 and invasion in immortalized urothelial cells

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 6, 2008, Pages 641-645

  Gee, Jason ^a   Lee, I Ling ^b   Grossman, H Barton ^b   Sabichi, Anita L ^b  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cyclooxygenase 2; Prostaglandin E2; Transitional cell carcinoma

Indexed keywords

CRYSTAL VIOLET; CYCLOOXYGENASE 2; MATRIGEL; PROSTAGLANDIN E2;

ARTICLE; CARCINOGENICITY; CELL GROWTH; CELL IMMORTALIZATION; CELL INVASION; CELL ISOLATION; CLONE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; UROTHELIUM; VECTOR CONTROL; WESTERN BLOTTING;

CELL LINE; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; NEOPLASM INVASIVENESS; TRANSFECTION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 55249102040     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.015     Document Type: Article

References (28)

1. DuBois R.N., Arbramson S.B., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
2. Mohammed S.I., Knapp D.W., Bostwick D.G., et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59 (1999) 5647-5650
3. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
4. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst 94 (2002) 252-266
5. Okie S. Raising the safety bar-the FDA's coxib meeting. N Engl J Med 352 (2005) 1283-1285
6. Gee J., Sabichi A.L., and Grossman H.B. Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol 43 (2002) 277-288
7. Blanke C.D., Mattek N.C., Deloughery T.G., et al. A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins Other Lipid Mediat 75 (2005) 169-172
8. Nugent F.W., Mertens W.C., Graziano S., et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: A multicenter phase II trial. Lung Cancer 48 (2005) 67-73
9. Dandekar D.S., Lopez M., Carey R.I., et al. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115 (2005) 484-492
10. Chiu C.H., McEntee M.F., and Whelan J. Sulindac causes rapid regression of preexisting tumors in -/+ mice independent of prostaglandin biosynthesis. Cancer Res 57 (1997) 4267-4273
11. Meisner L.F., Wu S.Q., Reznikoff C.A., et al. Cytogenetic instability with balanced chromosome changes in an SV40 transformed human uro epithelial cell line. Cancer Res 48 (1988) 3215-3220
12. Appleby S.B., Ristimaki A., Hla T., et al. Structure of the human cyclo-oxygenase-2 gene. Biochem J 302 (1994) 723-727
13. Davies M.A., Lu Y., Sano T., et al. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58 (1998) 5285-5290
14. Baelde H.J., Cleton-Jansen A.M., van Beerendonk H., et al. High quality RNA isolation from tumors with low cellularity and high extracellular matrix component for cDNA microarrays: Application to chondrosarcoma. J Clin Pathol 54 (2001) 778-782
15. Liu C.H., Chang S.-H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276 (2001) 18563-18569
16. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30 (2000) 3-21
17. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
18. 2 increases growth and motility of colorectal carcinoma cells. J. Biol Chem 276 (2001) 18075-18081
19. DuBois R.N., Radhika A., Reddy B.S., et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110 (1996) 1259-1262
20. Boolbol S.K., Dannenberg A.J., Chadburn A., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56 (1996) 2556-2560
21. Grubbs C.J., Lubet R.A., Koki A.T., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60 (2000) 5599-5602
22. Giovanucci E., Rimm E.B., Stampfer M.J., et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Int Med 121 (1994) 241-246
23. Castelao J.E., Yuan J.M., Gago-Dominguez M., et al. Nonsteroidal anti-inflammatory drugs and bladder cancer. Br J Cancer 82 (2000) 1364-1369
24. Gee J., Lee I.-L., Jendiroba D., et al. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15 (2006) 471-477
25. 2. Cancer Res 61 (2001) 81-87
26. 2 in human colon cancer cells. Cancer Res 58 (1998) 362-366
27. Cheng J., Huang H., Zhang Z.-T., et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 62 (2002) 4157-4163
28. Gee J.R., Montoya R.G., Khaled H.M., et al. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 21 (2003) 266-270